scholarly journals Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin

2021 ◽  
Vol 62 (4) ◽  
pp. 3
Author(s):  
Niels J. Brouwer ◽  
Eleni K. Konstantinou ◽  
Evangelos S. Gragoudas ◽  
Marina Marinkovic ◽  
Gregorius P. M. Luyten ◽  
...  
Keyword(s):  
Conjunctival Melanoma

Fluorescent in situ hybridization (FISH): A useful diagnostic tool for childhood conjunctival melanoma

2021 ◽  
pp. 112067212110307
Author(s):  
Raquel María Moral ◽  
Carlos Monteagudo ◽  
Javier Muriel ◽  
Lucía Moreno ◽  
Ana María Peiró
Keyword(s):  
In Situ Hybridization ◽  
Fluorescent In Situ Hybridization ◽  
Pediatric Population ◽  
Diagnostic Technique ◽  
Histopathological Diagnosis ◽  
Fish Analysis ◽  
Conjunctival Melanoma ◽  
Adequate Treatment ◽  
First Case

Introduction: Conjunctival melanoma is extremely rare in children and has low rates of resolution. Definitive histopathological diagnosis based exclusively on microscopic findings is sometimes difficult. Thus, early diagnosis and adequate treatment are essential to improve clinical outcomes. Clinical case: We present the first case in which the fluorescent in situ hybridization (FISH) diagnostic technique was applied to a 10-year-old boy initially suspected of having amelanotic nevi in his right eye. Based on the 65% of tumor cells with 11q13 (CCND1) copy number gain and 33% with 6p25 (RREB1) gain as measured by the FISH analysis, and on supporting histopathological findings, the diagnosis of conjunctival melanoma could be made. Following a larger re-excision, adjuvant therapy with Mitomycin C (MMC), cryotherapy and an amniotic membrane graft, the patient has remained disease-free during 9 years of long-term follow-up. Case discussion: Every ophthalmologist should remember to consider and not forget the possibility of using FISH analyses during the differential diagnosis of any suspicious conjunctival lesions. Genetic techniques, such as FISH, have led to great advances in the classification of ambiguous lesions. Evidence-based guidelines for diagnosing conjunctival melanoma in the pediatric population are needed to determine the most appropriate strategy for this age group.

scholarly journals Conjunctival melanoma treatment outcomes in 288 patients: a multicentre international data-sharing study

2020 ◽  
pp. bjophthalmol-2020-316293
Author(s):  
Puneet Jain ◽  
Paul T Finger ◽  
Maria Fili ◽  
Bertil Damato ◽  
Sarah E Coupland ◽  
...  
Keyword(s):  
Local Recurrence ◽  
Local Excision ◽  
External Beam Radiotherapy ◽  
Staging System ◽  
Primary Treatment ◽  
Excision Biopsy ◽  
Conjunctival Melanoma ◽  
Recurrence Rates ◽  
Increased Risk ◽  
Eighth Edition

BackgroundTo relate conjunctival melanoma characteristics to local control.MethodsRetrospective, registry-based interventional study with data gathered from 10 ophthalmic oncology centres from 9 countries on 4 continents. Conjunctival melanoma patients diagnosed between January 2001 and December 2013 were enrolled in the study. Primary treatments included local excision, excision with cryotherapy and exenteration. Adjuvant treatments included topical chemotherapy, brachytherapy, proton and external beam radiotherapy (EBRT). Cumulative 5-year and 10-year Kaplan-Meier local recurrence rates were related to clinical and pathological T-categories of the eighth edition of the American Joint Committee on Cancer (AJCC) staging system.Results288 patients had a mean initial age of 59.7±16.8 years. Clinical T-categories (cT) were cT1 (n=218,75.7%), cT2 (n=34, 11.8%), cT3 (n=15, 5.2%), cTx (n=21,7.3%) with no cT4. Primary treatment included local excision (n=161/288, 55.9%) followed by excision biopsy with cryotherapy (n=108/288, 37.5%) and exenteration (n=5/288, 1.7%). Adjuvant therapies included topical mitomycin (n=107/288, 37.1%), plaque-brachytherapy (n=55/288, 19.1%), proton-beam (n=36/288, 13.5%), topical interferon (n=20/288, 6.9%) and EBRT (n=15/288, 5.2%). Secondary exenteration was performed (n=11/283, 3.9%). Local recurrence was noted in 19.1% (median=3.6 years). Cumulative local recurrence was 5.4% (3.2–8.9%), 19.3% (14.4–25.5%) and 36.9% (26.5–49.9%) at 1, 5 and 10 years, respectively. cT3 and cT2 tumors were twice as likely to recur than cT1 tumours, but only cT3 had statistically significantly greater risk of local recurrence than T1 (p=0.013). Factors such as tumour ulceration, plica or caruncle involvement and tumour thickness were not significantly associated with an increased risk of local recurrence.ConclusionThis multicentre international study showed that eighth edition of AJCC tumour staging was related to the risk of local recurrence of conjunctival melanoma after treatment. The 10-year cumulative local recurrence remains high despite current management.

scholarly journals Conjunctival melanoma and electrochemotherapy: preliminary results using 2D and 3D cell culture models in vitro

2018 ◽  
Vol 97 (4) ◽  
pp. e632-e640 ◽  
Author(s):  
Miltiadis Fiorentzis ◽  
Periklis Katopodis ◽  
Helen Kalirai ◽  
Berthold Seitz ◽  
Arne Viestenz ◽  
...  
Keyword(s):  
Cell Culture ◽  
3D Cell Culture ◽  
Conjunctival Melanoma ◽  
Preliminary Results ◽  
Culture Models ◽  
2D And 3D ◽  
Cell Culture Models

Conjunctival Melanoma

2016 ◽  
pp. 803-811 ◽  
Author(s):  
Sarah E. Coupland ◽  
Raymond Barnhill ◽  
R. Max Conway ◽  
Bertil E. Damato ◽  
Bita Esmaeli ◽  
...  
Keyword(s):  
Conjunctival Melanoma

A Murine Model for Metastatic Conjunctival Melanoma

2015 ◽  
Vol 56 (4) ◽  
pp. 2325 ◽  
Author(s):  
Nadine E. de Waard ◽  
Jinfeng Cao ◽  
Sean P. McGuire ◽  
Paraskevi E. Kolovou ◽  
Ekaterina S. Jordanova ◽  
...  
Keyword(s):  
Murine Model ◽  
Conjunctival Melanoma

Case Study 162 Conjunctival Melanoma

2013 ◽  
pp. 369-370
Author(s):  
Roger P. Harrie ◽  
Cynthia J. Kendall
Keyword(s):  
Conjunctival Melanoma

scholarly journals Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma

2018 ◽  
Vol 136 (11) ◽  
pp. 1236 ◽  
Author(s):  
Oded Sagiv ◽  
Sudip D. Thakar ◽  
Thomas J. Kandl ◽  
Joshua Ford ◽  
Matthew C. Sniegowski ◽  
...  
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Conjunctival Melanoma ◽  
Programmed Cell Death 1

scholarly journals Conjunctival melanoma: association of cyclooxygenase-2 tumour expression to prognosis

2017 ◽  
Vol 95 ◽  
Author(s):  
R. Pinto Proença ◽  
M. Santos ◽  
C. Fonseca ◽  
J. Fernandes ◽  
M.F. Gaspar ◽  
...  
Keyword(s):  
Cyclooxygenase 2 ◽  
Conjunctival Melanoma
Sign in / Sign up

Export Citation Format

Share Document